Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer

Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD). The concept of Total Mesopancreas Excision (TMpE), analogous to total mesorectal excision, aims to improve oncological outcomes by achieving higher R0 resection rates through the comprehensive removal of retroperitoneal connective tissue surrounding major peripancreatic vessels. This single arm prospective study will evaluate the prognostic outcomes, primarily Disease- Free Survival (DFS) at 24 months, of a standardized TMpE technique performed during pancreaticoduodenectomy for resectable pancreatic head cancer. Secondary objectives include assessing Overall Survival (OS), R0 resection rates, recurrence patterns, and perioperative outcomes in 90 consecutive patients.

NCT Number	NCT07232810
Lead Sponsor	Minia University
Conditions	Pancreatic Head Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment	90 participants
Start Date	2025-12-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2027-12-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-02